✦ LIBER ✦

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer : A cost-effectiveness analysis

✍ Scribed by Rodney P. Rocconi; Ashley S. Case; J. Michael Straughn Jr.; Jacob M. Estes; Edward E. Partridge

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 144 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22045

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Centralization of care for patients with

Centralization of care for patients with advanced-stage ovarian cancer : A cost-effectiveness analysis

✍ Robert E. Bristow; Antonio Santillan; Teresa P. Diaz-Montes; Ginger J. Gardner; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to evaluate the cost‐effectiveness of centralized referral of patients with advanced‐stage epithelial ovarian cancer who underwent primary cytoreductive surgery and adjuvant chemotherapy. ## METHODS. A decision‐analysis model was used to

A phase 1 and pharmacodynamic study of d

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer

✍ Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

## Abstract ## BACKGROUND: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian c

Role of salvage chemotherapy with topote

Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: A phase II pilot study

✍ Ghamande, Sharad A.; Piver, M. Steven 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

## Background and Objectives: We assessed the role of salvage chemotherapy with topotecan and cisplatin in patients with platinum-and paclitaxel-resistant advanced and recurrent ovarian or primary peritoneal cancer, based on the reported in vivo and in vitro synergism between these two drugs. Meth

Pharmacoeconomic profile of paclitaxel a

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis

✍ Andrea Messori; Michele Cecchi; Paola Becagli; Sabrina Trippoli 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL. predisposes patients to the deve

Imatinib mesylate in combination with do

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : A Hoosier Oncology Group trial

✍ Daniela Matei; Robert E. Emerson; Jeanne Schilder; Nancy Menning; Lee Ann Baldri 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 485 KB 👁 1 views

Estimating survival gain for economic ev

Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

✍ N. Neymark; I. Adriaenssen; T. Gorlia; S. Caleo; M. Bolla 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 240 KB 👁 1 views

## Abstract The problem of estimating expected outcomes for the economic evaluation of treatments for which the outcome of principal interest is (quality adjusted) survival time has so far not received sufficient attention in the literature. The best estimate of expected survival is mean survival t